Hilda Mekelenkamp

Ms. Hilda Mekelenkamp

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2025 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
RGRaffaella Greco
Raffaella Greco
ARA. Ruggeri
A. Ruggeri
DMD. P. McLornan
D. P. McLornan
JSJ. A. Snowden
J. A. Snowden
TATobias Alexander
Tobias Alexander
ASAnna Sureda
Anna Sureda
For over two decades, the EBMT has updated recommendations on indications for haematopoietic cell transplantation (HCT) practice based on clinical and scientific developments in the field. This is the ninth special EBMT report on indications for HCT for haematological diseases, solid tumours and immune disorders. Our aim is to provide guidance on HCT indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered with the risk of the disease, risk of HCT procedure and non-HCT strategies, including evolving cellular therapies, and their availability on site. HCT techniques are constantly evolving and we make no specific recommendations, but encourage harmonisation of practice, where possible, to ensure experience across indications can be meaningfully aggregated via registry outputs. We also recommend working according to JACIE certification standards to maintain quality in clinical and laboratory practice, including benchmarking of survival outcomes [1,2,3]. Since the last edition, innovative cellular and gene therapies have entered in activity across indications affecting clinical decision making. As the number and type of regulatory authority-approved cellular therapies grow, recommendations for best practice and quality of patient care were developed to support clinicians and will be regularly updated.

10 January 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
EDElisabeth Dovern
Elisabeth Dovern
SNSterre J.A.M. Nijland
Sterre J.A.M. Nijland
MMMaud M. van Muilekom
Maud M. van Muilekom
LSLiesbeth M.J. Suijk
Liesbeth M.J. Suijk
GHGerianne M. Hoogendoorn
Gerianne M. Hoogendoorn
ENErfan Nur
Erfan Nur
Patients with sickle cell disease (SCD) experience a considerable physical and psychosocial disease burden. In recent years, the application of allogeneic hematopoietic stem cell transplantation (HSCT) to treat adults with SCD has increased. A thorough understanding of patients' physical, mental, and social health before and after cure is needed to meet the needs of this growing group of patients. We aimed to explore the perspectives of adult SCD patients on the changes in their experienced health and personal life goals after being cured. A mixed-methods approach was used, comprising a semistructured interview and a set of 9 Patient Reported Outcomes Measurement Information System (PROMIS) measures. Adult SCD patients who underwent HSCT at least 1 year earlier were eligible to participate in the study. Interviews were thematically analyzed using MAXQDA software. PROMIS T scores were compared with reference scores of the general population using SPSS Statistics. Ten patients participated in the study; their median age was 29.5 years (range, 19 to 49 years), and their median time since HSCT was 2.7 years (range, 1.0 to 3.5 years). Themes from the interviews were (1) pain/living pain free, (2) physical well-being, (3) mental well-being, (4) perspective/ outlook, (5) education/work, (6) family/friends, and (7) activities/participation. Following the PROMIS framework, we described these themes in a narrative synthesis according to health domain and categorized in 4 chronological time phases: before HSCT, first year post-transplantation, current situation, and future expectations. Physical health improved greatly, but transplantation-related toxicity, ongoing pain from avascular osteonecrosis, and fatigue negatively impacted quality of life in some patients. Furthermore, emotional struggles during the post-transplantation period were common, and patients expressed a need for psychological help. Patients reported improvements in social health and the ability to pursue personal life goals. The mean T scores of all PROMIS measures fell within the normal symptom limits compared with reference data of the general population, although, large variations were observed among the participants, matching our qualitative findings. In general, adult SCD patients experienced improved physical, mental, and social health after cure by HSCT and were able to pursue personal life goals. Yet they found themselves confronted with a new and unfamiliar reality that brought different challenges. Pain due to irreversible avascular osteonecrosis continued to have a negative impact. Clinicians should aim to help patients have realistic expectations before transplantation and offer timely psychological care.

5 March 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
HMHilda Mekelenkamp
Hilda Mekelenkamp
ALArjan C. Lankester
Arjan C. Lankester
MBMarc B. Bierings
Marc B. Bierings
FSFrans J.W. Smiers
Frans J.W. Smiers
MVMartine C. de Vries
Martine C. de Vries
MKMarijke C. Kars
Marijke C. Kars
Background: In pediatric hematopoietic stem cell transplantation (HSCT), the end‐of‐life (EOL) phase and the loss of the child is often characterized by a sudden deterioration of the child following a period of intensive curative treatment. This demands a fast transition for parents. Therefore, an understanding of the parents’ perspective on decision‐making in such a complex situation is needed. This study aims to gain insight in parental experiences in EOL decision‐making in allogeneic pediatric HSCT.Methods: A qualitative descriptive study was performed among parents of eight families. Data were thematically analyzed.Results: All parents were aware of their child's deterioration. Six families were confronted with a rapid deterioration, while two families experienced a gradual realization that their child would not survive. Parental EOL decision‐making in pediatric HSCT shows a reflective perspective on the meaning of parenthood in EOL decision‐making. Two central themes were identified: “survival‐oriented decision‐making” and “struggling with doubts in hindsight.” Six subthemes within the first theme described the parents’ goal of doing everything to achieve survival.Discussion: Parents experienced EOL decision‐making mainly as a process guided by health care professionals (HCPs) based on the child's condition and treatment possibilities. The decision‐making is characterized by following opportunities and focusing on hope for cure. In hindsight parents experienced doubts about treatment steps and their child's suffering. HCPs can strengthen the parental role by an early integration of palliative care, providing timely support to parents in the process of imminent loss. Advance care planning can be used to support communication processes, defining preferences for future care.

18 May 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Open access
PDF file
HMHilda Mekelenkamp
Hilda Mekelenkamp
FSFrans Smiers
Frans Smiers
NCNomie Camp
Nomie Camp
FSFabienne Stubenrouch
Fabienne Stubenrouch
ALArjan Lankester
Arjan Lankester
MVMartine de Vries
Martine de Vries
Background: Hematopoietic stem cell transplantation (HSCT) offers an established curative option for sickle cell disease (SCD) and thalassemia patients but is associated with significant risks. Decision making is a complex process and shared decision making (SDM) could be a fitting approach in case of such preference‐sensitive decisions. This study investigated what level of SDM is used in conversations with hemoglobinopathy patients and/or their caregivers considering HSCT as a curative treatment option.Methods: Longitudinal, descriptive study using the Observing‐Patient‐Involvement‐in‐Decision‐Making scale (OPTION5) scale to determine the level of SDM in conversations with 26 hemoglobinopathy patients and/or their caregivers.Results: The total mean OPTION5 score was 43%, which is a moderate SDM approach. There was no difference between conversations with thalassemia patients and SCD patients. Conversations needing an interpreter scored worse than nontranslated conversations. The best scoring OPTION5 item was item 3: “informing about the various treatment options” (mean score 2.3 on scale 0–4). For OPTION5 item 4: “eliciting patients’ preferences” a more skilled effort was measured for SCD patients compared to thalassemia patients.Conclusions: The mean OPTION5 score of “moderate” was achieved mainly by giving information on available options, which is primarily a one‐way communication. The SDM process can be improved by actively inviting patients to deliberate about options and including their elicited preferences in decision making.

21 July 2021 in Children
Verified
Journal Article
Open access
PDF file
HMHilda Mekelenkamp
Hilda Mekelenkamp
TSTeija Schröder
Teija Schröder
EAEugenia Trigoso Arjona
Eugenia Trigoso Arjona
DHDaphna Hutt
Daphna Hutt
JGJacques-Emmanuel Galimard
Jacques-Emmanuel Galimard
PPPaediatric Diseases Working Party
Paediatric Diseases Working Party
Hematopoietic stem cell transplantation (HSCT) is widely used in pediatric patients as a successful curative therapy for life-threatening conditions. The treatment is intensive, with risks of serious complications and lethal outcomes. This study aimed to provide insight into current data on the place and cause of death of transplanted children, the available specialized pediatric palliative care services (SPPCS), and what services HSCT professionals feel the SPPCS team should provide. First, a retrospective database analysis on the place and cause of death of transplanted pediatric HSCT patients was performed. Second, a survey was performed addressing the availability of and views on SPPCS among HSCT professionals. Database analysis included 233 patients of whom the majority died in-hospital: 38% in the pediatric intensive care unit, 20% in HSCT units, 17% in other hospitals, and 14% at home or in a hospice (11% unknown). For the survey, 98 HSCT professionals from 54 centers participated. Nearly all professionals indicated that HSCT patients should have access to SPPCS, especially for pain management, but less than half routinely referred to this service at an early stage. We, therefore, advise HSCT teams to integrate advance care planning for pediatric HSCT patients actively, ideally from diagnosis, to ensure timely SPPCS involvement and maximize end-of-life preparation.

18 August 2021 in Frontiers in Pediatrics
Verified
Journal Article
Open access
HMHilda Mekelenkamp
Hilda Mekelenkamp
HZHerma van Zanten
Herma van Zanten
MVMartine de Vries
Martine de Vries
ALArjan Lankester
Arjan Lankester
FSFrans Smiers
Frans Smiers
Hematopoietic stem cell transplantation decision-making for hemoglobinopathy patients is a complex process, and it remains difficult for health care professionals to decide whether and when a hematopoietic stem cell transplantation should be offered. Gaining insight into health care professionals' considerations is required to understand and optimize this decision-making process. A qualitative interview study using semi-structured interviews with eighteen health care professionals. Data were thematically analyzed. Two main themes emerged from the data: (1) Experiencing the influence of a frame of reference and (2) Feeling responsible for a guided decision-making. The frame of reference, meaning the health care professionals' knowledge and experiences regarding hematopoietic stem cell transplantation, influenced the guided decision-making process. Subsequently, three subthemes evolved from the second theme: (a) weighing up disease severity against possible complications, (b) making an effort to inform, and (c) supporting the best fitting decision for the individual patient. The health care professionals' frame of reference determined the hematopoietic stem cell transplantation decision-making process. This demands reflection on the health care professionals' own frame of reference and its influence on decision-making. Furthermore, reflection on the frame of reference is needed by exchange of knowledge and experiences between referring and referred-to healthcare professionals in an open and two-way direction. The transplantation teams have a responsibility of keeping the frame of reference of their referring colleagues up to date and referring health care professionals should share their feelings regarding hematopoietic stem cell transplantation. To guide patients, a shared decision-making approach is supportive, in which eliciting the patients' preferences is highly important. Health care professionals can refine the decision-making process by guiding patients in eliciting their preferences and including these in the decision.